Lipopolysaccharide and hypoxia significantly alters interleukin-8 and macrophage chemoattractant protein-1 production by human fibroblasts but not fibrosis related factors

Hippokratia

Volumn 15, Issue 3, 2011, Pages 238-243

  Eleftheriadis, T ^a,b   Liakopoulos, V ^b   Lawson, B ^c   Antoniadi, G ^b   Stefanidis, I ^b   Galaktidou, G ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Cobalt chloride; Fibroblast; Fibrosis; Hypoxia; Infection; Interlukin 8; Lipopolysaccharide; Monocyte chemoattractant protein 1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL FUNCTION; CELL HYPOXIA; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

EID: 79959853033     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol. 2007; 257: 143-179.
2. Kisseleva T, Brenner DA. Fibrogenesis of parenchymal organs. Proc Am Thorac Soc. 2008; 5: 338-342.
3. Jordana M, Sarnstrand B, Sime PJ, Ramis I. Immune-inflammatory functions of fibroblasts. Eur Respir J. 1994; 7: 2212-2222.
4. Kurt-Jones EA, Sandor F, Ortiz Y, Bowen GN, Counter SL, Wang TC, et al. Use of murine embryonic fibroblasts to define Toll-like receptor activation and specificity. J Endotoxin Res. 2004; 10: 419-424.
5. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology. 2003; 124: 1866-1878.
6. Wang PL, Azuma Y, Shinohara M, Ohura K. Toll-like receptor 4-mediated signal pathway induced by Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts. Biochem Biophys Res Commun. 2000; 273: 1161-1167.
7. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004; 4: 617-629.
8. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282: 2085-2088.
9. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997; 272: 19253-19260.
10. Poulios E, Trougakos IP, Gonos ES. Comparative effects of hypoxia on normal and immortalized human diploid fibroblasts. Anticancer Res. 2006; 26: 2165-2168.
11. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331: 1286-1292.
12. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115: 209-218.
13. Matsushima K, Morishita K, Yoshimura T, Lavu S, Kobayashi Y, Lew W, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med. 1988; 167: 1883-1893.
14. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987; 84: 9233-9237.
15. Rennekampff HO, Hansbrough JF, Kiessig V, Dore C, Sticherling M, Schroder JM. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res. 2000; 93: 41-54.
16. Baggiolini M. Chemokines in pathology and medicine. J Intern Med. 2001; 250: 91-104.
17. Strieter RM, Koch AE, Antony VB, Fick RB, Jr., Standiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med. 1994; 123: 183-197.
18. DiPietro LA, Polverini PJ, Rahbe SM, Kovacs EJ. Modulation of JE/MCP-1 expression in dermal wound repair. Am J Pathol. 1995; 146: 868-875.
19. Dipietro LA, Reintjes MG, Low QE, Levi B, Gamelli RL. Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen. 2001; 9: 28-33.
20. Semenza GL. Life with oxygen. Science. 2007; 318: 62-64.
21. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol. 2005; 37: 535-540.
22. Fandrey J, Gorr TA, Gassmann M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res. 2006; 71: 642-651.
23. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004; 4: 499-511.
24. Baccala R, Gonzalez-Quintial R, Lawson BR, Stern ME, Kono DH, Beutler B, et al. Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol. 2009; 5: 448-456.
25. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest. 2007; 117: 549-556.
26. Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF, 3rd, Gay RE, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci U S A. 2005; 102: 2892-2897.
27. Tsuchiya A, Imai K, Asamitsu K, Waguri-Nagaya Y, Otsuka T, Okamoto T. Inhibition of inflammatory cytokine production from rheumatoid synovial fibroblasts by a novel IkappaB kinase inhibitor. J Pharmacol Exp Ther. 333: 236-243.
28. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, et al. A selective small molecule IkappaB. Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther. 2006; 317: 989-1001.
29. Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S, et al. Is NF-kappaB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis. 2002; 61 Suppl 2: ii13-18.
30. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008; 586: 4055-4059.
31. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxiainducible factor-1alpha by NF-kappaB. Biochem J. 2008; 412: 477-484.
32. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008; 453: 807-811.
33. Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, et al. Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford). 2008; 47: 834-839.
34. Cha HS, Ahn KS, Jeon CH, Kim J, Song YW, Koh EM. Influence of hypoxia on the expression of matrix metalloproteinase-1,-3 and tissue inhibitor of metalloproteinase-1 in rheumatoid synovial fibroblasts. Clin Exp Rheumatol. 2003; 21: 593-598.
35. Galindo M, Santiago B, Alcami J, Rivero M, Martin-Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts. Clin Exp Immunol. 2001; 123: 36-41.
36. Safronova O, Nakahama K, Onodera M, Muneta T, Morita I. Effect of hypoxia on monocyte chemotactic protein-1 (MCP-1) gene expression induced by Interleukin-1beta in human synovial fibroblasts. Inflamm Res. 2003; 52: 480-486.
37. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol. 2003; 284: L899-914.
38. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57: 1009-1014.
39. Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP expression in chronic ulcers. Arch Dermatol Res. 1998; 290 Suppl: S47-54.
40. Schmid P, Cox D, Bilbe G, McMaster G, Morrison C, Stahelin H, et al. TGF-beta s and TGF-beta type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J Pathol. 1993; 171: 191-197.
41. Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem. 1988; 263: 7741-7746.
42. Xu Q, Norman JT, Shrivastav S, Lucio-Cazana J, Kopp JB. In vitro models of TGF-beta-induced fibrosis suitable for highthroughput screening of antifibrotic agents. Am J Physiol Renal Physiol. 2007; 293: F631-640.
43. Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Tasken K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2008; 20: 235-245.
44. Boeuf P, Vigan-Womas I, Jublot D, Loizon S, Barale JC, Akanmori BD, et al. CyProQuant-PCR: a real time RT-PCR technique for profiling human cytokines, based on external RNA standards, readily automatable for clinical use. BMC Immunol. 2005; 6: 5-18.
45. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989; 84: 1045-1049.
46. Low QE, Drugea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, et al. Wound healing in MIP-1alpha(-/-) and MCP-1(-/-) mice. Am J Pathol. 2001; 159: 457-463.
47. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther. 2009; 16: 1131-1162.
48. Chao CY, Cheing GL. Microvascular dysfunction in diabetic foot disease and ulceration. Diabetes Metab Res Rev. 2009; 25: 604-614.